The first promotes the differentiation and activity of Treg, while the second minimizes the extent of CD8+ effector T cell (Teff) infiltration into the tumor microenvironment.14–16 Consequently, activation of β-cat results in T cell exclusion, resistance to immunotherapy, and shortened survival of colon cancer patients. The gene discussed is CD8A; the disease is malignant colon neoplasm.